| ASSET | YEAR | % RETURN |
|---|---|---|
Erasca (ERAS) | 2026 | 394.88% |
MaxLinear (MXL) | 2026 | 381.32% |
Anterix (ATEX) | 2026 | 363.06% |
Ichor (ICHR) | 2026 | 342.99% |
Immunitybio (IBRX) | 2026 | 333.66% |
Ultra Clean (UCTT) | 2026 | 247.28% |
FuelCell Energy (FCEL) | 2026 | 247.06% |
Veradermics (MANE) | 2026 | 243.53% |
Tango Therapeutics (TNGX) | 2026 | 240.34% |
AXT (AXTI) | 2026 | 238.08% |
Definium Therapeutics (DFTX) | 2026 | 229.48% |
Enliven Therapeutics (ELVN) | 2026 | 228.52% |
Aehr Test Systems (AEHR) | 2026 | 218.46% |
Penguin Solutions (PENG) | 2026 | 215.44% |
Applied Opt (AAOI) | 2026 | 214.79% |
Maase (MAAS) | 2026 | 207.41% |
Sellas Life Sciences (SLS) | 2026 | 203.37% |
Alumis (ALMS) | 2026 | 199.59% |
P3 Health Partners (PIII) | 2026 | 197.46% |
Iridium Communications (IRDM) | 2026 | 194.31% |
BlackBerry (BB) | 2026 | 190.58% |
Spyre Therapeutics (SYRE) | 2026 | 187.64% |
Twist Bioscience (TWST) | 2026 | 186.89% |
Vishay Intertechnology (VSH) | 2026 | 186.6% |
Oruka Therapeutics (ORKA) | 2026 | 178.79% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.